



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 08, 2009

Zydus Pharmaceuticals (USA) Inc.

[View the current Zydus Pharmaceuticals \(USA\) Inc. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32281-Zydus+Pharmaceuticals+%28USA%29+Inc..html)

(<http://www.bioportfolio.com/biocorporate/32281-Zydus+Pharmaceuticals+%28USA%29+Inc..html>)

Contact Details:

**508 Carnegie Center Suite 101
Princeton
New Jersey
08540
United States of America**

Tel: (609)275-5125
Fax: (609)275-0499
Email: sales@zydususa.com

Zydus Pharmaceuticals (USA) Inc. is a globally integrated generic pharmaceutical company with a focus on providing high service, quality and affordable products. Our leadership, which has over 40 years of US generic market experience, understands our customer's business which allows Zydus Pharmaceuticals the ability to provide unique models to help drive their success. Though a new company in the US market, our parent Zydus Cadila has a large presence in the global markets, including relationships with many top tier international pharmaceutical companies. Based on a manufacturing and development history that spans over 50 years, our experience and knowledge affords us the ability to have one of the largest and most aggressive DMF and finished product pipelines in the industry.

Over the next three years we will be filing on average two additional products and DMFs per month. Through 2005 we will exceed that goal by filing 30 products and 28 DMFs. We're ready now to support that growth with the largest, state-of-the-art, cGMP, FDA approved formulation plant in India boasting a capacity near 12 billion units. We also have two FDA approved API plants with capacities exceeding 280 metric tons. Our sustained release technology and ability to manufacture tablet, capsule, soft gel, sterile liquids, injectables, inhalers, and trans-dermal patch dosage forms allows us to target even the most difficult of products. Once manufactured, our packaging area is equipped to handle special customer requests such as bulk, unit-of-use, blister, and consumer product packaging.

Press Releases on Zydus Pharmaceuticals (USA) Inc.:

[Plan's Expertise Highlighted at Premier Health Forum](#)

6th November,
2009

Plan USA

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- Plan International, a leading children's development organization with offices in 66 countries around the world, has been asked to deliver eight

Watson to Present at Credit Suisse Healthcare Conference	6th November, 2009	Watson Pharmaceuticals, Inc.	MORRISTOWN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's president and
Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering	6th November, 2009	Trius Therapeutics, Inc.	SAN DIEGO, Nov. 6 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a
DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009	6th November, 2009	DUSA Pharmaceuticals, Inc.	WILMINGTON, Mass., Nov. 6 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan (PDT) and
Lockton and Concentra Working Together to Lower Healthcare Costs for Employers	6th November, 2009	Lockton Benefit Group	-- Health risk assessments With a working relationship spanning a decade, Lockton and Concentra have developed and deployed innovative, customized solutions for clients that provide high

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months

old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

